VSP-17, a New PPARγ Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer Via Upregulating the Expression of E-Cadherin

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Jan 11

PMID 29316690

Citations 6

Authors

Yuhui Wang

Menglin Zhu

Bo Yuan

Kefeng Zhang

Mingli Zhong

Wei Yi

Xiaotian Xu

Xiaoqun Duan

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer, shows higher metastases and relapse rates than other subtypes. The metastasis of TNBC is the main reason for the death of TNBC patients. Increasing evidence has shown that inhibiting the metastasis of TNBC is a good method for TNBC treatment. Here, VSP-17 was designed and synthesized as an agonist of PPARγ, evidenced by upregulating the expression of CD36 and increasing the activity of PPARγ reporter gene. VSP-17 obviously inhibited the migration and invasion process of MDA-MB-231 cells but showed little effect on the viability of MDA-MB-231 cells. Notably, VSP-17 could selectively promote the expression of E-cadherin without affecting the expression of BRMS1, CXCL12, MMP9, Orai1, Stim1, TGF-β, and VEGF. In addition, VSP-17 significantly suppressed the metastasis of liver and promoted the expression of E-cadherin in MDA-MB-231 xenograft model. In conclusion, VSP-17 inhibited the metastasis process of TNBC via upregulating the expression of E-cadherin.

Citing Articles

Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.

Hermawan A, Putri H BMC Genom Data. 2022; 23(1):72.

PMID: 36114448 PMC: 9482259. DOI: 10.1186/s12863-022-01086-2.

PPAR-γ Modulators as Current and Potential Cancer Treatments.

Chi T, Wang M, Wang X, Yang K, Xie F, Liao Z Front Oncol. 2021; 11:737776.

PMID: 34631571 PMC: 8495261. DOI: 10.3389/fonc.2021.737776.

PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy.

Augimeri G, Bonofiglio D Biomedicines. 2021; 9(5).

PMID: 34067944 PMC: 8152061. DOI: 10.3390/biomedicines9050543.

VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway.

Xu X, Liu M, Yang Y, Wei C, Zhang X, Song H Oncol Rep. 2021; 45(3):975-986.

PMID: 33650675 PMC: 7859999. DOI: 10.3892/or.2020.7916.

Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment.

Fernandez L, Gomez de Cedron M, Ramirez de Molina A Front Oncol. 2020; 10:577420.

PMID: 33194695 PMC: 7655926. DOI: 10.3389/fonc.2020.577420.

References

Mehner C, Hockla A, Miller E, Ran S, Radisky D, Radisky E . Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014; 5(9):2736-49. PMC: 4058041. DOI: 10.18632/oncotarget.1932. View

Ondrey F . Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res. 2009; 15(1):2-8. DOI: 10.1158/1078-0432.CCR-08-0326. View

Liu H, Zang C, Fenner M, Possinger K, Elstner E . PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat. 2003; 79(1):63-74. DOI: 10.1023/a:1023366117157. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Liu Y, Liu Z, Chen Y, Xu K, Dong J . PPARγ activation reduces ischemia/reperfusion-induced metastasis in a murine model of hepatocellular carcinoma. Exp Ther Med. 2016; 11(2):387-396. PMC: 4734081. DOI: 10.3892/etm.2015.2934. View

Colmers I, Bowker S, Johnson J . Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2012; 38(6):475-84. DOI: 10.1016/j.diabet.2012.06.003. View

Choi J, Banks A, Kamenecka T, Busby S, Chalmers M, Kumar N . Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature. 2011; 477(7365):477-81. PMC: 3179551. DOI: 10.1038/nature10383. View

Jamdade V, Sethi N, Mundhe N, Kumar P, Lahkar M, Sinha N . Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015; 172(17):4228-37. PMC: 4556464. DOI: 10.1111/bph.13211. View

Belfiore A, Genua M, Malaguarnera R . PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res. 2009; 2009:830501. PMC: 2709717. DOI: 10.1155/2009/830501. View

10.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

11.

Roberti M, Arriaga J, Bianchini M, Quinta H, Bravo A, Levy E . Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther. 2012; 13(11):1123-40. PMC: 3461818. DOI: 10.4161/cbt.21187. View

12.

Anderson K, Schwab R, Martinez M . Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014; 144(1):1-10. PMC: 4026199. DOI: 10.1007/s10549-014-2852-7. View

13.

Bojkova B, Garajova M, Kajo K, Pec M, Kubatka P, Kassayova M . Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev. 2010; 19(5):379-84. DOI: 10.1097/CEJ.0b013e32833ca233. View

14.

Bayraktar S, Gluck S . Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2013; 138(1):21-35. DOI: 10.1007/s10549-013-2421-5. View

15.

Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S . Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014; 19(6):608-15. PMC: 4041678. DOI: 10.1634/theoncologist.2014-0002. View

16.

Zardavas D, Baselga J, Piccart M . Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013; 10(4):191-210. DOI: 10.1038/nrclinonc.2013.29. View

17.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

18.

Ravinuthala R, Nori U . Rosiglitazone toxicity. Ann Intern Med. 2000; 133(8):658. DOI: 10.7326/0003-4819-133-8-200010170-00025. View

19.

Motiani R, Hyzinski-Garcia M, Zhang X, Henkel M, Abdullaev I, Kuo Y . STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch. 2013; 465(9):1249-60. PMC: 3748246. DOI: 10.1007/s00424-013-1254-8. View

20.

Burstein H, Demetri G, Mueller E, Sarraf P, Spiegelman B, Winer E . Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003; 79(3):391-7. DOI: 10.1023/a:1024038127156. View